Henin Beaumont

This research aims to collect long-term safety and effectiveness information on commercially available Corin hip arthroplasty devices. It focuses on patients who have had hip replacement surgery using Corin implants, including those with primary, secondary, or post-traumatic osteoarthrosis, femur head necrosis, congenital dislocations, and revision surgeries. The study supports post-market surveillance and clinical evaluations of these devices. Participants are patients with hip implants from Corin. The study observes their outcomes over many years, starting during surgery and continuing up to 20 years after. Key evaluations include clinical performance, safety, radiological positioning and bone integration of the implants, as well as patient quality of life and satisfaction at various intervals. During the study, participants will undergo assessments at multiple time points including 3 months, 2.5 years, and up to 20 years after surgery. Researchers will collect data on implant outcomes, patient well-being, and implant safety. The main measure is the long-term outcome at 10 years, with additional follow-ups at 15 and 20 years to monitor ongoing performance and safety. The total duration of participation can extend up to 30 years from the start date.

Researchers are conducting an observational study to gather long-term safety and performance data on hip hemiarthroplasty surgeries using Corin BiPolar-i shell along with the Oceane or Meije Duo femoral stems. This study responds to the need for more clinical evidence under the new Medical Device Regulation MDR for these Corin devices in hip hemiarthroplasty. The study focuses on patients with conditions like osteoarthritis, avascular necrosis, femoral neck fractures, and related hip disorders where only half of the hip joint is replaced. Participants undergo hip hemiarthroplasty surgery with Corin devices including the BiPolar-i shell and either the Oceane or Meije Duo cemented femoral stems. The study follows these patients for up to 10 years to collect comprehensive data on device safety and how well the devices perform in supporting mobility and quality of life. This includes radiographic assessments to monitor bone and device status, such as acetabular erosion, femoral stem stability, and bipolar head migration. During the study, participants will attend scheduled follow-up visits extending up to 10 years after surgery. Researchers will evaluate safety outcomes primarily at 2 years and continue monitoring mid- and long-term safety and device benefits up to 10 years. Data collection involves clinical examinations, radiographic imaging, and patient-reported measures of mobility and quality of life. The study aims to provide valuable information on the performance of these hip devices over time, ensuring ongoing safety and patient wellbeing.

Researchers are investigating kidney cancer through the UroCCR network, a national registry and research platform in France that collects detailed real-world data on patient care and disease progression. Established in 2011, this extensive database includes over 21,000 cases from 58 centers and links clinical information with annotated biological samples and national health data. The platform supports multiple types of research, including translational studies, clinical evaluations, and social science investigations, aiming to improve understanding and management of renal cell carcinoma. The study involves adult patients diagnosed with kidney cancer and documents their treatments, including procedures such as radical or partial nephrectomy as determined by the surgeon. Data collected encompasses clinical parameters, imaging, patient-reported outcomes, and socioeconomic factors. The registry supports prospective research projects and ancillary studies, with a focus on real-world practice following national guidelines. It also integrates digital tools for monitoring and prediction, enhancing personalized treatment strategies. Participants contribute data continuously from enrollment through long-term follow-up, which may last until death or withdrawal. The study collects comprehensive clinical, biological, imaging, and patient-reported information, along with biological samples like plasma, urine, and tumor tissue. Researchers measure outcomes related to research project promotion, biological sample collection, epidemiology, treatment monitoring, quality of life, biomarker research, and clinical practice evaluation. This ongoing data collection supports knowledge advancement and improved kidney cancer care over many years.